Drug intelligence / Profile preview

TEE786

Development stage: Preclinical
Lead developer: Apteeus
Modality: Small Molecules

Overview

TEE786 is a small molecule therapeutic candidate being developed by the French biotechnology company Apteeus for the treatment of skin fibrosis. The compound was identified using Apteeus's proprietary TEEpS (Therapeutic Efficiency Evaluation on Patients' Cells) platform, which utilizes high-throughput screening on patient-derived cells to discover or reposition treatments for rare and complex diseases. As of 2024, TEE786 is in the preclinical stage of development. While it is specifically targeted toward fibrotic skin conditions, its exact molecular mechanism of action and specific biological target have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on TEE786.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TEE786.

Explore the full profile